STOCK TITAN

Natera Inc - NTRA STOCK NEWS

Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.

Overview of Natera Inc

Natera Inc (symbol: NTRA) is a San Carlos, California-based diagnostic and research company that integrates advanced NIPT, bioinformatic, and molecular diagnostic technologies to improve genetic and genomic testing. Leveraging breakthroughs from the human genome project, the company specializes in non-invasive prenatal testing, preimplantation genetic diagnosis, and advanced oncology diagnostics. By employing sophisticated proprietary algorithms, Natera delivers high accuracy and reliability across a spectrum of tests, ensuring couples and patients receive critical genetic insights at every stage of care.

Core Services and Product Categories

Natera has developed a comprehensive portfolio of tests that address various healthcare challenges:

  • Non-Invasive Prenatal Testing (NIPT): Utilizing a simple blood draw from the mother, Natera’s Panorama test offers in-depth chromosomal screening, enabling early detection of genetic conditions with minimum risk during pregnancy.
  • Carrier Screening: Through Horizon Carrier Screening, the company assesses carrier status for numerous genetic conditions, helping prospective parents understand and manage risks associated with severe genetic diseases.
  • Oncology Diagnostics: The Signatera test is designed for molecular residual disease assessment in cancer patients, providing clinicians a tool to detect circulating tumor DNA and monitor treatment effectiveness post-therapy.
  • Transplant Rejection Assessment: The Prospera test assists in monitoring organ transplant recipients by evaluating rejection risk, thereby supporting post-transplant care management.

Technological Innovation and Expertise

Natera’s edge in the competitive diagnostic landscape lies in its pioneering use of bioinformatic algorithms and molecular science. The integration of advanced computing with genetic analysis allows the company to transform raw genomic data into actionable clinical insights. This is particularly significant in the fields of prenatal and oncology testing, where early and accurate diagnosis can have lasting impacts on patient management and treatment decisions. The company continuously applies insights from the latest genomic research to refine and expand its testing services.

Market Position and Industry Significance

Within the diagnostic and genetic testing space, Natera distinguishes itself through its commitment to precision and reliability. The firm occupies a unique niche where technological innovation meets clinical application, serving diverse patient groups including expectant couples, individuals undergoing fertility treatments, cancer survivors, and organ transplant recipients. Its tests are designed for use in specialized clinical settings, further emphasizing the role of expert genetic counseling and technical support in achieving accurate results. This multidimensional approach not only enhances patient care but also supports broader efforts in personalized medicine and informed clinical decision-making.

Integration of Molecular Diagnostics and Genomic Informatics

The success of Natera’s offerings is rooted in its detailed understanding of genomic data and its translation into diagnostic solutions. The company applies rigorous scientific methods and robust bioinformatic systems to parse complex genomic information and deliver clear, actionable reports. This disciplined approach not only builds trust with healthcare providers and patients alike but also sets a high standard for the industry by ensuring that every result is backed by proven science and extensive expertise.

Commitment to Informed Clinical Decisions

From conception to ongoing health management, Natera’s testing methodologies empower clinicians and patients with essential genetic insights. The company emphasizes informed decision-making by combining advanced technology with comprehensive genetic counseling. This ensures that testing results are interpreted accurately and contextualized within each patient’s unique clinical profile, supporting better outcomes and safer health journeys.

Understanding Natera in the Competitive Landscape

In a market that is increasingly reliant on precision diagnostics, Natera stands out by focusing on the reliability and depth of its genetic tests. Although competitive pressures exist from other diagnostic firms, Natera’s unique blend of molecular diagnostics and bioinformatics uniquely positions it to address complex genetic challenges across multiple conditions. The company’s detailed-oriented approach and commitment to scientifically validated testing procedures underline its reputation among healthcare professionals and investors aiming to understand the nuances of genetic diagnostics.

Rhea-AI Summary

Natera (NASDAQ: NTRA) has announced a new peer-reviewed study validating its Signatera molecular residual disease (MRD) assay for oligometastatic colorectal cancer (oligo mCRC). The study involved 112 patients and demonstrated that Signatera identified MRD positivity in 54% of cases post-surgery, with a sensitivity of 72%. Serial testing increased sensitivity to 91%, with 100% overall survival among those who remained MRD-negative. These findings aim to establish Signatera as a vital prognostic biomarker for guiding treatment decisions in this patient population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary

Natera, a leader in cell-free DNA testing, announced the pricing of its public offering of 4,500,000 shares at $113.00 each, with expected closing on July 26, 2021. The offering includes a 30-day option for underwriters to buy an additional 675,000 shares. The offering is underpinned by a shelf registration statement filed with the SEC. Morgan Stanley, Goldman Sachs, Cowen, and SVB Leerink are managing the offering. Natera aims to enhance disease management globally, focusing on women's health, oncology, and organ health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
none
-
Rhea-AI Summary

Natera, Inc. (Nasdaq: NTRA) has announced a proposed follow-on public offering to raise $350 million through the sale of its common stock. Additionally, underwriters may purchase up to $52.5 million more in shares. The offering is contingent on market conditions, and there are no guarantees regarding its completion or the terms. Major banks including Morgan Stanley and Goldman Sachs are managing the offering. This move is part of Natera's ongoing efforts to fund its operations and expand its impact in cell-free DNA testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
none
Rhea-AI Summary

Natera, Inc. (Nasdaq: NTRA) reported preliminary financial results for the second quarter of 2021, showcasing record growth. Expected revenues range from $138 million to $141 million, marking a 60% year-on-year increase from $86.5 million in Q2 2020. Product revenues are anticipated to be $135 million to $137 million, a 70% rise from $80.4 million in the same period last year. The company also processed approximately 370,000 tests, up 58% from 234,000. However, a loss from operations is projected between $113 million and $117 million, compared to $51.7 million in Q2 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.78%
Tags
none
-
Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) presented new data on its molecular residual disease (MRD) assay, Signatera, at the ESMO GI 2021 conference. This includes results from the CIRCULATE-Japan trial, the largest MRD-guided study in colorectal cancer (CRC), featuring over 800 patients. Signatera demonstrated a 93.1% sensitivity for relapse detection, showcasing improved disease-free survival rates for MRD-negative patients. The study is pivotal in potentially altering early-stage CRC treatment guidelines and underscores the significance of personalized MRD testing for patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
-
Rhea-AI Summary

Natera, a leader in cell-free DNA testing, partners with BGI Genomics to launch the BGI/Natera Signatera Assay in China. This assay, which detects molecular residual disease in various cancers, enables earlier identification compared to standard imaging. Launched two years after their partnership, the assay supports innovative trial design and offers biopharmaceutical companies opportunities for companion diagnostic registrations in both China and the U.S. The collaboration aims to enhance precision medicine and improve treatment outcomes for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
Rhea-AI Summary

Natera (NASDAQ: NTRA) has received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services (CMS) for its Signatera molecular residual disease (MRD) test. The initial reimbursement rate for each Signatera assay is set at $3,500. This test is instrumental in monitoring cancer recurrence, having shown efficacy up to two years prior to conventional imaging methods. With over 3,000 patients studied, Signatera has received three Breakthrough Device Designations from the FDA. Natera aims to expand access to this innovative testing technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
Rhea-AI Summary

Natera (NASDAQ: NTRA) announced a study published in Nature validating its Signatera ctDNA assay's ability to predict immunotherapy outcomes. This marks Signatera's 12th peer-reviewed publication and the first demonstrating the predictive capabilities of a molecular residual disease (MRD) test in a large randomized trial. Key findings included a 41% improvement in overall survival for ctDNA-positive patients treated with atezolizumab, compared to those under observation alone. The results suggest Signatera could enhance personalized cancer therapy and patient stratification.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
Rhea-AI Summary

Foundation Medicine and Natera, Inc. (NASDAQ: NTRA) have launched the research use version of FoundationOne Tracker, a personalized ctDNA monitoring assay. This innovative product combines Foundation Medicine's genomic profiling with Natera's ctDNA expertise, targeting both advanced and early-stage research applications. The partnership aims to streamline the workflow for including ctDNA monitoring results in retrospective studies, thereby enhancing drug development in oncology. Executives from both companies predict that this tool will help establish personalized ctDNA monitoring as a standard oncology care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
partnership
Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, announced its participation in the American Transplant Congress (ATC) 2021 Virtual Connect from June 4-9. The company will present new scientific data on its Prospera test, which evaluates organ transplant rejection. Presentations include findings from leading physicians, emphasizing the importance of cfDNA in timely decision-making for nephrologists. The Prospera test enhances rejection assessment by measuring donor-derived cfDNA, having shown improved sensitivity in recent studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
none

FAQ

What is the current stock price of Natera (NTRA)?

The current stock price of Natera (NTRA) is $140.65 as of April 1, 2025.

What is the market cap of Natera (NTRA)?

The market cap of Natera (NTRA) is approximately 19.0B.

What core services does Natera Inc offer?

Natera Inc offers a suite of genetic testing services, including non-invasive prenatal testing, carrier screening, oncology diagnostics, and transplant rejection assessments. Each service is supported by advanced bioinformatic algorithms and molecular technologies.

How does Natera ensure accuracy in its testing processes?

Natera leverages proprietary bioinformatic algorithms and rigorous scientific methods to process complex genomic data. This technology-driven approach underpins the accuracy and reliability of its prenatal, oncology, and other genetic tests.

What is non-invasive prenatal testing (NIPT) and how does Natera apply it?

Non-invasive prenatal testing (NIPT) involves screening for genetic abnormalities through a simple maternal blood draw. Natera’s Panorama test applies this technique to provide early genetic insights and reduce risks associated with invasive testing methods.

What role does bioinformatics play in Natera's diagnostic solutions?

Bioinformatics is central to Natera’s approach, converting raw genomic data into clinically actionable insights. The integration of computing with molecular diagnostics allows the company to deliver detailed, accurate results across its testing portfolio.

How does Natera address the needs of oncology patients?

Through its Signatera test, Natera detects circulating tumor DNA to monitor molecular residual disease in cancer patients. This aids in evaluating treatment effectiveness and detecting potential recurrence, thereby supporting informed clinical decisions.

In what ways does Natera contribute to the field of genetic diagnostics?

Natera is at the forefront of advancing genetic diagnostics by integrating cutting-edge molecular science with innovative bioinformatic techniques. This combination ensures highly accurate testing in prenatal, reproductive, and oncology settings.

How is Natera positioned within the competitive landscape of diagnostic companies?

Natera distinguishes itself by focusing on precise, scientifically validated testing and comprehensive genetic counseling services. While facing competition from similar diagnostic firms, its unique blend of technology and expertise sets it apart in specialized clinical applications.
Natera Inc

Nasdaq:NTRA

NTRA Rankings

NTRA Stock Data

19.05B
130.00M
3.45%
93.67%
2.13%
Diagnostics & Research
Services-medical Laboratories
Link
United States
AUSTIN